Acknowledgements
This study is sponsored by MacroGenics, Inc. The authors thank all of the patients, their families and the entire staff who participated in this trial. We would like to thank S. Shankar, E. Rock and J. Wigginton for their contributions to the clinical development of tebotelimab; J. Muth, N. Yee-Toy, J. Koucheki and E. Adeishvili for patient sample tracking and coordination of analyses; J. Seiler and K. Grossi for serving as the regulatory leads of the study; T. Sherwood for PD-L1 IHC scoring; R. La Motte-Mohs, J. R. Rillema, H. Li, S. Gorlatov, S. Burke, V. Ciccarone, S. Saini-Lal, M. Licea, C. Fieger, F. Vasanwala and J. Saul for antibody and DART molecule generation and analyses; Y. (S.) Ma Trang Pham for supporting clinical data analyses; S. Church and colleagues for NanoString analyses; S. Kaul for pharmacokinetic analyses; E. Bonvini and A. Ward for manuscript review; and S. Koenig for support from concept through clinical studies. The following authors received grants from MacroGenics: J.J.L. G.B., E.H., B.C. and S.V.U. Professional medical writing support in the preparation of this report was provided by E. Marcantoni, E. Cullinan and F. Balordi of The Lockwood Group, in accordance with Good Publication Practice (GPP 2022) guidelines, with funding by MacroGenics, Inc.